Piasky
What Piasky is used for
Piasky as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age or older with a weight of 40 kg and above with paroxysmal nocturnal haemoglobinuria (PNH): In patients with haemolysis with clinical symptom(s) indicative of high disease activity. In patients who are clinically stable after having been treated with a complement component 5 (C5) inhibitor for at least the past 6 months.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Piasky
- Active substance
- crovalimab
- Disease area
- Hemoglobinuria, Paroxysmal
- Medicine group
- Immunosuppressants, Complement inhibitors
- ATC code
- L04AJ07
- Marketing authorisation holder
- Roche Registration GmbH
- Authorised in the EU since
- 2024
Official information
In the USA
Same active substance: Piasky
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Piasky used for?
Piasky as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age or older with a weight of 40 kg and above with paroxysmal nocturnal haemoglobinuria (PNH): In patients with haemolysis with clinical symptom(s) indicative of high disease activity. In patients who are clinically stable after having been treated with a complement component 5 (C5) inhibitor for at least the past 6 months.
What is the active substance in Piasky?
Piasky contains crovalimab.
Who makes Piasky?
The EU marketing authorisation holder is Roche Registration GmbH.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU